NCT02219893View on ClinicalTrials.gov

Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 10, 2016

Study Completion Date

December 10, 2016

Conditions

Colorectal Neoplasms

Interventions

DRUG

MOC31PE Immunotoxin

Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC

Trial Locations (1)

0424

Oslo University Hospital- The Norwegian Radium Hospital, Oslo

All Listed Sponsors

lead

Oslo University Hospital

OTHER

NCT02219893 - Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial | Biotech Hunter | Biotech Hunter